Immune system analysis and immune modulation is at the core of our individualized diagnosis and treatment program. Importantly, we pay a lot of attention to the exact analysis of the current immunological status, which not only includes the analysis of lymphocytes subpopulations but also measuring the balance of cancer killing cells and cancer suppressing cells (TH1/TH2 balance, TReg cells) and the analysis of important cytokines mediating/suppressing the immune response (IL-6, IL-10, TNF, soluble IL-2). Only this exact analysis allows us to stimulate and modulate the immune system in an individual manner.
Immunotherapy for cancer patients is experiencing a global renaissance. In particular, the recently approved checkpoint inhibitors (PDL-1 / PD-1 and CTLA-4 antibodies) have currently achieved a breakthrough in oncology in indications previously considered totally incurable.
Checkpoint inhibitors ensure that cancer cells cannot switch off the attack by the body’s own immune cells. Our body’s own defense system (immune system) serves to protect against diseases. It becomes active, for example, when there is an infection with pathogens such as bacteria or viruses (immune reaction).
But it is also of great importance for the fight against cancer cells. Certain defense cells (the so-called T cells) are particularly important. Under certain conditions they can recognize and destroy cancer cells. In the case of many immune reactions, it is important that they stop after the cause has been eliminated (e.g. when an infection has subsided). This is why there are so-called receptors on certain cells of the immune system that are responsible for controlling the immune response (checkpoints).
In simplified terms, these receptors can be imagined as switches through which cells of the immune system can be activated or deactivated. The switches for the T cells are called checkpoint receptors. Cancer cells can bind to the checkpoint receptors and thus switch off the T cells. In this way, the cancer cells escape the attack of the immune system or at least weaken it. Checkpoint inhibitors are special proteins (antibodies) that prevent cancer cells from binding to the checkpoint receptors. They can also increase the activation of T cells. The T cells remain activated and are better able to fight the cancer cells. This is why checkpoint inhibitors are used as drugs to treat certain cancers.
However, checkpoint inhibitors can cause other immune reactions in the body to be more violent (immune related adverse effects irAE). Checkpoint inhibitors are given as an intravenous infusion. They can be administered alone (as monotherapy) or in combination with other drugs such as cytostatics of parallel to radiation therapy
We have found that the combination of these checkpoint inhibitors with hyperthermia and an immunotherapy that has been established worldwide for 30 years shows particularly good results:
We combine the aforementioned checkpoint inhibitors with local hyperthermia and whole-body hyperthermia as well as interleukin-2 (IL-2) .
Immunotherapy for cancer patients with low dose check point inhibitor followed by interleukin 2 (IL-2) and Taurolidine is a very powerful immunotherapy to specifically stimulate the so- called T cell response in cancer patients.
This way we are able to offer this therapy in a safe and effective manner. Our patients will be monitored in our clinic. This therapy can only be performed for patients carrying a Port-A-Cath system.
Your individualized treatment plan will be tailored to your personal needs taking into consideration all medical and human aspects.